Venture capital fund · 1 deal
Every published round MainSequence took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Kinoxis Therapeutics | Unnamed stage | 23 Sep 2026 | $6.8m | Participant | Dynamic Business, This Week in Australian Startups, Uniseed, Dealroom, Startup Daily |
Companies MainSequence has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Kinoxis Therapeutics | 23 Sep 2026 | 1 | 0 |
Fund closes reported for MainSequence, as distinct from the investments it has made.
Companies MainSequence has backed that another company then bought. An exit for the holding, not a deal MainSequence did.
Stories naming MainSequence. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Kinoxis completed a $6.75 million round with new backer MainSequence and won a $2.5 million government-funded CUREator+ grant for dementia and pain drug development; MainSequence's Elaine Stead joins the board.
Also Startup Daily·Startup Daily·Dealroom·This Week in Australian Startups·Dynamic Business